New trial evaluates investigational drug for endometrial and breast cancers

Dividing Breast Cancer Cell

Dividing Breast Cancer Cell
Photo credit: Wei Qian

Women with endometrial cancer or certain types of breast cancer may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Breast cancer is the most common malignancy diagnosed in women in the United States. Endometrial cancer, which is less common, starts when cells in the inner lining of the uterus begin to grow out of control. ONC201 is an investigational drug that in laboratory studies has been shown to kill breast and endometrial cancer cells most likely by destroying mitochondria within the tumor cells. Mitochondria are the “powerhouse” of the cell, and blocking their activity may kill tumor cells and shrink tumors in human patients. Alexandra Zimmer, M.D., of the Women’s Malignancies Branch is leading this study to see if ONC201 can shrink breast and endometrial tumors and determine how long the drug continues to work in women with these diseases. Learn more about the Women's Malignancies Branch research and the trials they support.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care.  Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: 04/2018